The popularity of Sildenafil initially sparked a surge for pharma, but recent changes present a uncertain picture for those considering a stake. Lower-cost versions are reducing revenue, and continued legal battles add https://siobhanpmka800821.blazingblog.com/41216267/the-blue-pill-and-big-pharma-a-risky-investment